Johnson & Johnson (JNJ -0.1%) finishes the day relatively flat, despite saying earlier that its Janssen Pharmaceuticals unit has been granted a positive opinion by the CHMP of the European Medicines Agency recommending approval of its prostate cancer treatment Zytiga.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs